目的：为提高急性心肌梗死（ Ａ Ｍ Ｉ） 病人的临床治愈率，改善预后。方法：在发病年龄、性别、心梗部位、临床特点、治疗方法及监测手段接近（ Ｐ＞ ００５） ，应用国产尿激酶，对早溶组和晚溶组两组７８ 例 Ａ Ｍ Ｉ 患者，进行静脉溶栓治疗。结果：早溶组和晚溶组，冠脉再通率７２５ ％ 和３９５ ％ （ Ｐ＜ ００５） ；病死率５ ％ 和１５８ ％ （ Ｐ＜ ００５） ；并发症早溶组明显低于晚溶组（ Ｐ＜ ００５） ；未见明显副作用。提示： Ａ Ｍ Ｉ早期静脉溶栓治疗是心肌再灌注的关键，时间越早，疗效越好，早期溶栓明显提高梗塞冠脉的再通率，显著降低死亡率，改善病人预后，减少并发症发生。以后长期应用阿司匹林、β受体阻滞剂，可改善心梗后生存率和预后。 Objective: To improve the clinical cure rate and improve the prognosis of patients with acute myocardial infarction (AMI). Methods: The age, gender, myocardial infarction site, clinical features, treatment methods and monitoring methods were close (P> 005) , For intravenous thrombolytic therapy. Results: The rate of coronary recanalization was 725% and 395% (P <005), and the case fatality rates were 5% and 158% (P <005) Symptoms of early solution group was significantly lower than the late dissolving group (P <0  05); no obvious side effects. Tip: A M I ​​early venous thrombolytic therapy is the key to myocardial reperfusion, the earlier the time, the better the effect of early thrombolysis significantly improve the recanalization rate of infarcted coronary artery, significantly reduce mortality, improve patient prognosis and reduce complications occur. Long-term use of aspirin, β-blockers, can improve post-MI survival and prognosis.